Treatment of Attention-Deficit/Hyperactivity Disorder with Medication in Children with Autism Spectrum Disorder With and Without Intellectual Disability: A DBPNet Study

被引:0
作者
Joanna E. Grater
Elisa I. Muniz
Ellen J. Silver
Nathan J. Blum
Justine Shults
Ruth E. K. Stein
机构
[1] Children’s Hospital at Montefiore,Perelman School of Medicine, Children’s Hospital of Philadelphia
[2] Albert Einstein College of Medicine,undefined
[3] University of Pennsylvania,undefined
来源
Journal of Autism and Developmental Disorders | 2023年 / 53卷
关键词
Autism; ADHD; Intellectual disability; Medication;
D O I
暂无
中图分类号
学科分类号
摘要
Children with autism spectrum disorder (ASD) and intellectual disability (ID)/global delay (GD) frequently have symptoms of attention-deficit/hyperactivity disorder (ADHD). We describe the practice patterns of developmental behavioral pediatricians (DBPs) in the treatment of children with ASD and coexisting ADHD and compare medication classes for children with and without intellectual disability. In bivariate analyses, we compared demographic characteristics, co-occurring conditions, and medication classes for children with and without intellectual disability. Significantly more patients with ID/GD were prescribed α-agonists than patients without ID/GD, but the difference was no longer significant when controlling for age in logistic regression children with ID/GD had more comorbidities and were more likely to be prescribed more than on psychotropic medication. In conclusion, age rather than ID/GD was associated with medication choice.
引用
收藏
页码:3144 / 3150
页数:6
相关论文
共 266 条
[1]  
Aman MG(2003)Methylphenidate treatment in children with borderline IQ and mental retardation: Analysis of three aggregated studies Journal of Child and Adolescent Psychopharmacology 13 29-40
[2]  
Buican B(1993)Fenfluramine and methylphenidate in children with mental retardation and ADHD: Clinical and side effects Journal of the American Academy of Child and Adolescent Psychiatry 32 851-859
[3]  
Arnold LE(1991)Clinical effects of methylphenidate and thioridazine in intellectually subaverage children Journal of the American Academy of Child and Adolescent Psychiatry 30 246-256
[4]  
Aman MG(2020)Society for developmental and behavioral pediatrics clinical practice guideline for the assessment and treatment of children and adolescents with complex attention-deficit/hyperactivity disorder Journal of Developmental and Behavioral Pediatrics 41 S35-S57
[5]  
Kern RA(2020)The society for developmental and behavioral pediatrics clinical practice guideline for the assessment and treatment of children and adolescents with complex attention-deficit/hyperactivity disorder: Process of care algorithms Journal of Developmental and Behavioral Pediatrics 41 S58-S74
[6]  
McGhee DE(2018)Common use of stimulants and alpha-2 agonists to treat preschool attention-deficit hyperactivity disorder: A DBPNet study Journal of Developmental and Behavioral Pediatrics 39 531-537
[7]  
Arnold LE(2016)Centers for disease and prevention prevalence and characteristics of autism spectrum disorder among children aged 8 years-autism and developmental disabilities monitoring network, 11 Sites, United States, 2012 MMWR Surveillance Summaries 65 1-23
[8]  
Aman MG(2013)Efficacy of atomoxetine for the treatment of ADHD symptoms in patients with pervasive developmental disorders: A prospective, open-label study Journal of Attention Disorders 17 497-505
[9]  
Marks RE(2006)Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD Journal of the American Academy of Child and Adolescent Psychiatry 45 1284-1293
[10]  
Turbott SH(1992)Effects and noneffects of methylphenidate in children with mental retardation and ADHD Journal of the American Academy of Child and Adolescent Psychiatry 31 455-461